In creating opportunities for early interaction on complex generic product development, the US FDA may have excited sponsors, but at the same time the agency also gave itself an incentive to prevent the system's use.
Absent product-specific guidance on a complex generic or an alternative equivalence evaluation where a development guidance has been issued, agency officials must
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?